Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pronota is to Receive Patent on Biomarker for Diagnosing Renal Failure

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
USPTO has allowed Company’s patent for the use of a blood-based biomarker LG3.

The United States Patent and Trade Office (USPTO) has allowed Pronota’s patent for the use of a blood-based biomarker LG3 in the decision-making process for the treatment of renal dysfunction.

This is a major step forward for Pronota as it reconfirms the patentability of the use of biomarkers.

A decision of the US Supreme Court in Mayo vs. Prometheus in March 2012 had questioned the patentability of the use of biomarkers as patents on diagnostic methods were regarded as claiming a natural law or phenomenon.

The diagnostic industry had been startled by this decision as use of biomarkers was seen as being directed to non-patentable subject-matter.

In close collaboration with the Biotech specialists of US agent Knobbe Martens Olson & Bear LLP (US), the European Patent Attorneys of Boxall IPM (UK) and De Clercq & Partners (Belgium), have now succeeded in reformulating the diagnostic method claims into an allowable format.

These claims provide Pronota with the protection it needs in the US to develop a test which will provide the clinicians with better tools for the evaluation and monitoring of treatment of renal dysfunction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-Term Pre-Eclampsia Cases
The test correctly identifies 80% of women at risk for the development of pre-term pre-eclampsia according to a study in collaboration with the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium.
Thursday, July 12, 2012
Pronota Strengthens Management Team
Former VP corporate development Genzyme joins as CBO.
Friday, March 16, 2012
Pronota Awarded Euro 1.87M Grant by Flanders Government
The grant will be used to expand the development of Pronota’s diagnostic and pharmacodiagnostic protein biomarker discovery and validation platform.
Tuesday, July 10, 2007
Scientific News
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
New Genetic Risk Factors for Myopia Discovered
Genes and environment determine short-sightedness.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Uncovering How Some Breast Cancers Resist Treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!